Pharmacokinetics of RO5072759 (GA101) In Patients with Relapsed/Refractory CD20+ Malignant Disease (Phase I/II Study BO20999)

被引：4
|
作者：
Meneses-Lorente, Georgina [1 ]
Carlile, David [1 ]
Birkett, Joe
Wenger, Michael K. [2 ]
Cartron, Guillaume [3 ]
Morschhauser, Franck [4 ]
Salles, Gilles Andre [5 ]
机构：
[1] Roche Prod Ltd, Clin Pharmacol, Welwyn Garden City AL7 3AY, Herts, England
[2] F Hoffmann La Roche Ltd, Basel, Switzerland
[3] Hop St Eloi, Serv Hematol Oncol Med, Montpellier, France
[4] Univ Hosp Lille, Lille, France
[5] Ctr Hosp Lyon Sud, F-69310 Pierre Benite, France
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
10.1182/blood.V116.21.1833.1833
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：765 / 765
页数：1
相关论文
共 50 条
  • [1] A Phase I/II Study of RO5072759 (GA101) in Patients with Relapsed/Refractory CD20+ Malignant Disease
    Salles, Gilles Andre
    Morschhauser, Franck
    Cartron, Guillaume
    Lamy, Thierry
    Milpied, Noel-Jean
    Thieblemont, Catherine
    Tilly, Herve
    Birkett, Joe
    Burgess, Mike
    BLOOD, 2008, 112 (11) : 93 - 93
  • [2] A Phase I Study of GA101 (RO5072759) Monotherapy Followed by Maintenance in Patients with Multiply Relapsed/Refractory CD20+ Malignant Disease
    Sehn, Laurie H.
    Assouline, Sarit E.
    Stewart, Douglas A.
    Mangel, Joy
    Pisa, Pavel
    Kothari, Jaimal
    Crump, Michael
    BLOOD, 2009, 114 (22) : 385 - 385
  • [3] RESULTS FROM A PHASE I/II STUDY (BO20999) OF RO5072759 (GA101) MONOTHERAPY IN RELAPSED/REFRACTORY NON-HODGKIN'S LYMPHOMA
    Salles, G.
    Morschhauser, F.
    Thieblemont, C.
    Celigny, P. Solal
    Lamy, T.
    Birkett, J.
    Cartron, G.
    ANNALS OF ONCOLOGY, 2011, 22 : 104 - 104
  • [4] RESULTS FROM A PHASE II STUDY (BO20999) OF RO5072759 (GA101) MONOTHERAPY IN RELAPSED/REFRACTORY AGGRESSIVE NON-HODGKIN'S LYMPHOMA
    Cartron, G.
    Thieblemont, C.
    Solal-Celigny, P.
    Morschhauser, F.
    Haioun, C.
    Bouabdallah, R.
    Wenger, M.
    Salles, G.
    ANNALS OF ONCOLOGY, 2011, 22 : 131 - 132
  • [5] Phase I Study of RO5072759 (GA101) in Relapsed/Refractory Chronic Lymphocytic Leukemia
    Morschhauser, Franck
    Cartron, Guillaume
    Lamy, Thierry
    Milpied, Noel-Jean
    Thieblemont, Catherine
    Tilly, Herve
    Weisser, Martin
    Birkett, Joe
    Salles, Gilles Andre
    BLOOD, 2009, 114 (22) : 364 - 364
  • [6] Phase I Study of RO5072759 (GA101) in Patients with Relapsed/Refractory CD20+Non-Hodgkin Lymphoma (NHL).
    Salles, Gilles
    Morschhauser, Franck
    Lamy, Thierry
    Milpied, Noel
    Thieblemont, Catherine
    Tilly, Herve
    Bieska, Gabi
    Carlile, David
    Cartron, Guillaume
    BLOOD, 2009, 114 (22) : 679 - 679
  • [7] Efficacy and Safety of Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma: Results From a Phase I/II Study (BO20999)
    Salles, Gilles Andre
    Morschhauser, Franck
    Thieblemont, Catherine
    Solal-Celigny, Philippe
    Lamy, Thierry
    Tilly, Herve
    Feugier, Pierre
    Le Gouill, Steven
    Gyan, Emmanuel
    Bouabdallah, Reda
    Wenger, Michael K.
    Wassner-Fritsch, Elisabeth
    Asikanius, Elina
    Cartron, Guillaume
    BLOOD, 2011, 118 (21) : 123 - 124
  • [8] Pharmacokinetics of Obinutuzumab (GA101) in Patients with CD20+Relapsed/Refractory Malignant Disease Receiving Concomitant Chemotherapy (Phase Ib Study BO21000)
    Carlile, David
    Meneses-Lorente, Georgina
    Wassner-Fritsch, Elisabeth
    Hourcade-Potelleret, Florence
    Wenger, Michael K.
    Cartron, Guillaume
    Vitolo, Umberto
    Radford, John
    Davies, Andrew
    Morschhauser, Franck
    BLOOD, 2011, 118 (21) : 1582 - 1583
  • [9] Encouraging Activity of Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma: Results From a Phase II Study (BO20999)
    Morschhauser, Franck
    Cartron, Guillaume
    Thieblemont, Catherine
    Solal-Celigny, Philippe
    Haioun, Corinne
    Bouabdallah, Reda
    Lamy, Thierry
    Milpied, Noel
    Le Gouill, Steven
    Feugier, Pierre
    Wenger, Michael K.
    Wassner-Fritsch, Elisabeth
    Asikanius, Elina
    Salles, Gilles Andre
    BLOOD, 2011, 118 (21) : 1562 - 1563
  • [10] Phase I and pharmacokinetics study of a novel anti-CD20 antibody, RO5072759 (GA101), in Japanese patients (Pts) with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) pretreated with rituximab
    Tobinai, K.
    Ogura, M.
    Hatake, K.
    Kobayashi, Y.
    Mori, M.
    Uchida, T.
    Suzuki, T.
    Terui, Y.
    Yokoyama, M.
    Hotta, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345